Reistone Reports Successful Test of JAK1 Inhibitor for Atopic Dermatitis

Reistone Biopharma of Shanghai reported its JAK1 inhibitor met both the primary and secondary endpoints in a China Phase II trial in patients with moderate-to-severe atopic dermatitis. At week 12, all doses of SHR0302 showed at least a 75% improvement in the Eczema Area Severity Index (EASI75) compared to placebo. Reistone in-licensed the candidate in 2018 from Jiangsu Hengrui Medicine, which backed Reistone at its founding. Reistone focuses on globalizing innovative drugs developed in China by companies like Hengrui. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.